Pulmonary Arterial Hypertension: Review of clinical candidates.
By Victoria Hudson, Senior Analyst
14 July 2014
I am the senior analyst for Datamonitor Healthcare’s cardiovascular and metabolic team, and cover everything from acut...
Read full bio
With three pipeline therapies entering the market in late 2013, the pulmonary arterial hypertension late-stage pipeline is looking increasingly underwhelming, with the exception of Actelion’s selexipag. Datamonitor Healthcare has analysed clinical candidates undergoing development in the PAH pipeline across the US, Japan and five major EU markets
How will our pulmonary arterial hypertension pipeline report benefit you?
- Identify market needs
Explore how the high demand for prostacyclin IP receptors is shaping the late-stage pipeline and which therapies are forecast to excel in this area once launched, allowing you to understand how developers are targeting this key unmet need and what drug attributes are necessary for commercial success
- Gain competitive insight
Compare novel pipeline therapies against marketed drugs through their clinical and commercial attributes, allowing you to gain valuable insight into the therapies with the highest commercial potential and how they fit within the market.
- Benchmark your trial design. Explore how Actelion’s use of innovative Phase III trial designs have helped to different its therapies from the competition, allowing you to understand how trial design in pulmonary arterial hypertension is changing and the impact this is having on the market.
Key questions answered:
- How will Actelion’s selexipag compare to the established therapies in PAH?
- What is the focus within the late-stage pipeline?
- What threats will pipeline drugs in pulmonary arterial hypertension face?
|Drug List:||Companies Mentioned:|
Posted in Cardiovascular.